Nasal polyposis and cystic fibrosis(CF): review of the literature

Feuillet‐Fieux, Marie‐Noëlle; Lenoir, G.; Sermet, Isabelle; Elie, Céline; Djadi-Prat, Juliette; Ferrec, M.; Magen, Maryse; Couloigner, V.; Manach, Yannick Le; Lacour, Bernard; Bonnefont, Jean‐Paul

doi:10.4193/rhino10.225

Cited by 32 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chinese and European polyps cannot be discriminated based on endoscopy but show a very different inflammatory pattern. The same holds true for polyps in patients with CF compared to non‐CF polyps 22, 23…”

Section: Discussionmentioning

confidence: 73%

See 1 more Smart Citation

Symptoms in chronic rhinosinusitis with and without nasal polyps

2012

View full text Add to dashboard Cite

Objectives/Hypothesis: In this study we analyzed differences in symptoms scored between chronic rhinosinusitis patients with (CRSwNP) and without nasal polyps (CRSsNP). According to the European Position Paper on Rhinosinusitis and Nasal Polyps, CRSwNP and CRSsNP diagnoses are defined by clinical criteria supported with endoscopy. We wanted to know if it is possible to make an accurate distinction between patients with and without nasal polyps based on clinical impression. Study Design: Retrospective case‐control study. Methods: We collected Rhinosinusitis Outcome Measure 31 (RSOM‐31) questionnaires from chronic rhinosinusitis patients with and without nasal polyps and compared mean total RSOM‐31 scores, mean domain scores, mean symptoms scores, and percentages of patients reporting symptoms per diagnosis based on endoscopy and computed tomography scan. Results: RSOM‐31 questionnaires were collected from 234 patients. Although the total RSOM‐31 score was similar and symptomatology considerably overlapping, patients with CRSwNP scored significantly higher and more often on nasal symptoms such as “rhinorrhea” and “decreased sense of taste or smell.” Patients with CRSsNP significantly scored more often and higher on “facial pain” and “ear pain.” Conclusions: Although there were significant differences in scores on several symptoms, there was considerable overlap of many symptoms, and it remains difficult to distinguish between CRSwNP and CRSsNP based on clinical impression alone. Laryngoscope, 2013

show abstract

Section: Discussionmentioning

confidence: 73%

“…The same holds true for polyps in patients with CF compared to non-CF polyps. 22,23 We dichotomized the data to account for the symptom frequency based on a symptom score of !2. This means patients grade their symptom as ''a mild or slight problem'' or worse.…”

Section: Discussionmentioning

confidence: 99%

Symptoms in chronic rhinosinusitis with and without nasal polyps

2012

View full text Add to dashboard Cite

show abstract

“…Many adult PwCF develop comorbid chronic rhinosinusitis (CRS) due to an inability to clear thick secretions from the upper airway and paranasal sinuses. Over half of adults with CF report symptomatic sinus disease, two-thirds have nasal polyposis, and nearly all have radiologic or endoscopic sinus inflammation ( 4 – 10 ). CF-related CRS is detrimental to quality of life (QOL) and associated with substantial productivity loss ( 11 – 16 ).…”

mentioning

confidence: 99%

Impact of Cystic Fibrosis Transmembrane Conductance Regulator Therapy on Chronic Rhinosinusitis and Health Status: Deep Learning CT Analysis and Patient-reported Outcomes

Beswick

Humphries²,

Balkissoon

et al. 2022

Annals ATS

View full text Add to dashboard Cite

Rationale Elexacaftor, tezacaftor, and ivacaftor (ETI) in triple combination improves pulmonary health for people with cystic fibrosis (PwCF). However, its impact on objective measures of sinus disease and health utility is unestablished. Objectives To evaluate the impact of ETI on chronic rhinosinusitis (CRS) and general health status incorporating computed tomography (CT), quality-of-life (QOL) and productivity loss. Methods Adult PwCF+CRS with CF transmembrane conductance regulator genotype F508del/F508del or F508del/minimal function who clinically initiated ETI participated in a prospective, observational study. The primary endpoint was change in percent sinus CT opacification (%SO) after 6 months of ETI assessed via deep learning-based methods. Secondary endpoints included changes in sinonasal QOL, health utility value and productivity loss, which were evaluated monthly via validated metrics. Results 30 PwCF provided baseline data; 25 completed the study. At baseline, the cohort had substantial CRS, with mean 22-question SinoNasal Outcome Test (SNOT-22) score 33.1 and mean sinus CT %SO 63.7%. At 6-month follow-up, %SO improved by mean 22.9% ( P < 0.001). %SO improvement trended toward greater magnitude for those naïve to prior modulator therapy ( P = 0.09). Mean SNOT-22 scores and health utility improved by 15.3 and 0.068 [6.8%] (all P ⩽ 0.007). Presenteeism, activity impairment and overall productivity loss improved (all P ⩽ 0.049). Improvements in SNOT-22 scores and health utility occurred by one month and remained improved over the study. Conclusions ETI is associated with substantial improvements in sinus CT opacification and productivity loss, and clinically meaningful improvements in sinonasal QOL and health utility. Most improvements were rapid, robust, and durable over the study.

show abstract

“…[90][91][92] Premorbid conditions as risk factors for CRS Patients with CF may constitute up to approximately 5% of patients with CRS, 86,93 with the incidence of CRS in CF ranging up to 100% and the incidence of NP ranging up to 50% depending on the study. [94][95][96] Similarly, patients with primary ciliary dyskinesia, which may be due to over 30 different gene mutations and has an incidence of 1 in 10,000-20,000 live births, 97 have up to 100% lifetime risk of developing CRS due to the associated deficit in mucociliary clearance. 98 Granulomatous diseases (eg, sarcoidosis) and vasculitides (eg, granulomatosis with polyangiitis [GPA] or eosinophilic granulomatosis with polyangiitis [EGPA]) include CRS as one of their disease manifestations and may occur in up to 3% of patients with CRS.…”

Section: Demographic Risk Factors For Crsmentioning

confidence: 99%